Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Halozyme Therapeutics Inc...

    NASDAQ: HALO · Real-Time Price · USD
    53.84
    1.04 (1.97%)
    At close: Jun 24, 2025, 3:59 PM
    53.90
    0.12%
    After-hours: Jun 24, 2025, 05:59 PM EDT

    Halozyme Therapeutics Statistics

    Share Statistics

    Halozyme Therapeutics has 123.22M shares outstanding. The number of shares has increased by -2.94% in one year.

    Shares Outstanding

    n/a
    		 123.22M

    Shares Change (YoY)

    n/a
    		 -2.94%

    Shares Change (QoQ)

    n/a
    		 -2.9%

    Owned by Institutions (%)

    n/a
    		 97.52%

    Shares Floating

    n/a
    		 121.86M

    Failed to Deliver (FTD) Shares

    n/a
    		 59,896

    FTD / Avg. Volume

    n/a
    		 2.67%

    Short Selling Information

    The latest short interest is 10.55M, so 8.56% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 10.55M

    Short % of Shares Out

    n/a
    		 8.56%

    Short % of Float

    n/a
    		 11.72%

    Short Ratio (days to cover)

    n/a
    		 5.21

    Valuation Ratios

    The PE ratio is 13.65 and the forward PE ratio is 7.36. Halozyme Therapeutics's PEG ratio is 0.21.

    PE Ratio

    n/a
    		 13.65

    Forward PE

    n/a
    		 7.36

    PS Ratio

    n/a
    		 5.97

    Forward PS

    n/a
    		 3.6

    PB Ratio

    n/a
    		 16.67

    P/FCF Ratio

    n/a
    		 12.95

    PEG Ratio

    n/a
    		 0.21
    Financial Ratio History

    Enterprise Valuation

    Halozyme Therapeutics has an Enterprise Value (EV) of 7.45B.

    EV / Sales

    n/a
    		 7.34

    EV / EBITDA

    n/a
    		 11.35

    EV / EBIT

    n/a
    		 15.56

    EV / FCF

    n/a
    		 15.91

    Financial Position

    The company has a current ratio of 7.8, with a Debt / Equity ratio of 4.14.

    Current Ratio

    n/a
    		 7.8

    Quick Ratio

    n/a
    		 6.78

    Debt / Equity

    n/a
    		 4.14

    Debt / EBITDA

    n/a
    		 2.29

    Debt / FCF

    n/a
    		 3.21

    Interest Coverage

    n/a
    		 30.48

    Financial Efficiency

    Return on Equity is 122.06% and Return on Invested Capital is 22.84%.

    Return on Equity

    n/a
    		 122.06%

    Return on Assets

    n/a
    		 21.52%

    Return on Invested Capital

    n/a
    		 22.84%

    Revenue Per Employee

    n/a
    		 $2,900,925.71

    Profits Per Employee

    n/a
    		 $1,268,831.43

    Employee Count

    n/a
    		 350

    Asset Turnover

    n/a
    		 0.49

    Inventory Turnover

    n/a
    		 1.12

    Taxes

    Income Tax

    n/a
    		 113.04M

    Effective Tax Rate

    n/a
    		 20.29%

    Stock Price Statistics

    The stock price has increased by 2.75% in the last 52 weeks. The beta is 1.19, so Halozyme Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.19

    52-Week Price Change

    n/a
    		 2.75%

    50-Day Moving Average

    n/a
    		 56.74

    200-Day Moving Average

    n/a
    		 55.77

    Relative Strength Index (RSI)

    n/a
    		 46.71

    Average Volume (20 Days)

    n/a
    		 2,244,135

    Income Statement

    In the last 12 months, Halozyme Therapeutics had revenue of 1.02B and earned 444.09M in profits. Earnings per share was 3.5.

    Revenue

    n/a
    		 1.02B

    Gross Profit

    n/a
    		 855.91M

    Operating Income

    n/a
    		 551.48M

    Net Income

    n/a
    		 444.09M

    EBITDA

    n/a
    		 656.54M

    EBIT

    n/a
    		 575.23M

    Earnings Per Share (EPS)

    n/a
    		 3.5
    Full Income Statement

    Balance Sheet

    The company has 115.85M in cash and 1.51B in debt, giving a net cash position of -1.39B.

    Cash & Cash Equivalents

    n/a
    		 115.85M

    Total Debt

    n/a
    		 1.51B

    Net Cash

    n/a
    		 -1.39B

    Retained Earnings

    n/a
    		 359.87M

    Total Assets

    n/a
    		 2.2B

    Working Capital

    n/a
    		 1.11B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 479.06M and capital expenditures -10.7M, giving a free cash flow of 468.37M.

    Operating Cash Flow

    n/a
    		 479.06M

    Capital Expenditures

    n/a
    		 -10.7M

    Free Cash Flow

    n/a
    		 468.37M

    FCF Per Share

    n/a
    		 3.69
    Full Cash Flow Statement

    Margins

    Gross margin is 84.3%, with operating and profit margins of 54.32% and 43.74%.

    Gross Margin

    n/a
    		 84.3%

    Operating Margin

    n/a
    		 54.32%

    Pretax Margin

    n/a
    		 54.87%

    Profit Margin

    n/a
    		 43.74%

    EBITDA Margin

    n/a
    		 64.66%

    EBIT Margin

    n/a
    		 54.32%

    FCF Margin

    n/a
    		 46.13%

    Dividends & Yields

    HALO does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 7.32%

    FCF Yield

    n/a
    		 7.72%
    Dividend Details

    Analyst Forecast

    The average price target for HALO is $65, which is 20.7% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $65

    Price Target Difference

    n/a
    		 20.7%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 9
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 $87.5

    Lynch Upside

    n/a
    		 62.52%

    Graham Number

    n/a
    		 15.03

    Graham Upside

    n/a
    		 -72.08%

    Scores

    Altman Z-Score

    n/a
    		 4.68

    Piotroski F-Score

    n/a
    		 8

    Add to Watchlist